RU94024812A - Method of poliomyelitis prophylaxis in extreme north - Google Patents

Method of poliomyelitis prophylaxis in extreme north

Info

Publication number
RU94024812A
RU94024812A RU94024812/14A RU94024812A RU94024812A RU 94024812 A RU94024812 A RU 94024812A RU 94024812/14 A RU94024812/14 A RU 94024812/14A RU 94024812 A RU94024812 A RU 94024812A RU 94024812 A RU94024812 A RU 94024812A
Authority
RU
Russia
Prior art keywords
years
age
months
serological
population
Prior art date
Application number
RU94024812/14A
Other languages
Russian (ru)
Inventor
И.А. Новицкий
Н.Н. Лащинская
А.В. Дубов
А.С. Килеев
Original Assignee
Институт медицинских проблем Севера СО РАМН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт медицинских проблем Севера СО РАМН filed Critical Институт медицинских проблем Севера СО РАМН
Priority to RU94024812/14A priority Critical patent/RU94024812A/en
Publication of RU94024812A publication Critical patent/RU94024812A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FIELD: medicine. SUBSTANCE: method involves the administration of living poliomyelitis vaccine. Settled population were vaccinated at the age 3; 4.5; 6 months; 3; 8; 17 years and above 17 years - according the results of serological inspection. Migratory population were vaccinated at the age from 3 months to 6 years three times at interval between vaccinations at least 1.5 month (not less); at the age 7 years - once (at positive serological inspection) or at the age 7, 13 and 17 years (at absence of serological inspection). EFFECT: enhanced effectiveness of prophylaxis.

Claims (1)

Изобретение относится к области медицины, а именно к педиатрии и может быть использовано для вакцинопрофилактики полиомиелита среди населения Крайнего Севера, ведущего кочевой и оседлый образ жизни. Способ включает введение живой полиомиелитной вакцины. Новым в способе является то, что население, ведущее оседлый образ жизни, вакцинируют в возрасте 3; 4,5 и 6 мес., 3 года, 8 лет, 17 лет, старше 17 лет по результатам серологического обследования, а население, ведущее кочевой образ жизни, - в возрасте от 3 мес. до 6 лет трехкратно с интервалами между прививками не менее 1,5 мес., в возрасте 7 лет - при положительном результате серологического обследования однократно, при отсутствии серологического контроля - последовательно в возрасте 7, 13 и 17 лет.The invention relates to medicine, namely to pediatrics and can be used for the vaccination of poliomyelitis among the population of the Far North, leading a nomadic and sedentary lifestyle. The method comprises administering a live polio vaccine. New in the method is that a sedentary population is vaccinated at the age of 3; 4.5 and 6 months, 3 years, 8 years, 17 years, over 17 years according to the results of a serological examination, and the population leading a nomadic lifestyle - from the age of 3 months. up to 6 years three times at intervals between vaccinations of at least 1.5 months, at the age of 7 years - with a positive result of serological examination once, in the absence of serological control - sequentially at the age of 7, 13 and 17 years.
RU94024812/14A 1994-06-29 1994-06-29 Method of poliomyelitis prophylaxis in extreme north RU94024812A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94024812/14A RU94024812A (en) 1994-06-29 1994-06-29 Method of poliomyelitis prophylaxis in extreme north

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94024812/14A RU94024812A (en) 1994-06-29 1994-06-29 Method of poliomyelitis prophylaxis in extreme north

Publications (1)

Publication Number Publication Date
RU94024812A true RU94024812A (en) 1996-05-10

Family

ID=48448093

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94024812/14A RU94024812A (en) 1994-06-29 1994-06-29 Method of poliomyelitis prophylaxis in extreme north

Country Status (1)

Country Link
RU (1) RU94024812A (en)

Similar Documents

Publication Publication Date Title
RU94042386A (en) Vaccine against hepatitis containing 3-o-deacylated monophosphoryl-lipid a, use of hepatitis antigen for preparing the preparation for hepatitis treatment, method of hepatitis treatment
RU94046232A (en) Vaccine composition, use of composition, treatment methods, method of composition preparing
DK0815235T3 (en) Vaccines against plague
YU47899B (en) PROCEDURE FOR OBTAINING PREPARATIONS PREVENTING THE TRANSMISSION OF SEXUAL DISEASES AND THE TAMPONS CONTAINING IT
Greenberg et al. Vaccination against rabies with duck-embryo and Semple vaccines
HUP0203335A1 (en) Vaccine
ATE150976T1 (en) VACCINE CONJUGATES FOR THE TREATMENT OF BIRD DISEASES
DE69527986D1 (en) ANTIGEN MEDICINE FOR TREATMENT OR PREVENTION
Habel Preparation of mumps vaccines and immunization of monkeys against experimental mumps infection
Payzin Epidemiological investigations on Q fever in Turkey
RU94024812A (en) Method of poliomyelitis prophylaxis in extreme north
US3397267A (en) Method of producing rabies vaccine
Peckinpaugh et al. Mass enteric live adenovirus vaccination during epidemic ARD
Smorodintsev et al. Results of a study of the reactogenic and immunogenic properties of live anti-poliomyelitis vaccine
FR2385401A1 (en) SYNCYTIAL RESPIRATORY VIRUS VACCINE
Hofman Poliomyelitis in the Netherlands 1958-69: the influence of a vaccination programme with inactivated poliovaccine
HU205264B (en) Process for producing vaccine against infective peritonitis of cat
Nicholson et al. Enteric inoculation with ERA rabies virus: evaluation of a candidate wildlife vaccine in laboratory rodents
Lowenthal et al. Eastern equine encephalomyelitis vaccine prepared in cell cultures
Olmsted Dermal fistulas of dental origin in children
Smorodintsev et al. Further experiences with live measles vaccines in USSR: use of virus propagated in chick fibroblasts and in guinea pig kidney cells
RU2185853C2 (en) Method for revaccination with alive sabin vaccine in the arctic
Francis et al. The response of Langerhans cells to palatal cover plates in the rat
RU1801212C (en) Method for selecting children for renewed vaccination against measles
Habel Advances in rabies research